HAEMONETICS CORP

This summary highlights selected information in this proxy statement (this "Proxy Statement"), which is being furnished in connection with the solicitation of proxies by Haemonetics Corporation for use at the 2025 Annual Meeting of Shareholders. Please review this entire Proxy Statement before voting. References in this Proxy Statement to "Haemonetics," the "Company," "we," "us" or "our" refer to Haemonetics Corporation.

Voting Roadmap

2025 ANNUAL MEETING OF SHAREHOLDERS

MEETING AGENDA AND VOTING RECOMMENDATIONS

HOW TO VOTE

HAEMONETICS CORPORATION | 2025 Proxy Statement 3

Performance Highlights

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. We view our operations and manage our business in three principal reporting segments: Plasma, Blood Center and Hospital. The Company’s common stock trades on the New York Stock Exchange ("NYSE") under the symbol "HAE."

Haemonetics' fiscal 2025 represented a strong installment in our multi-year, long-range plan targeting transformational growth, diversification and sustainability in our business. We achieved significant milestones in our business evolution and drove improved profitability and growth momentum as we navigated external market challenges, including rapidly evolving trends in electrophysiology, a temporary pullback in plasma collections, difficult market conditions in China and other macroeconomic uncertainties. In Hospital, we continued to strengthen our ability to compete in attractive, high-growth markets through differentiated enabling technologies and portfolio evolution, including the launches of our upsized VASCADE MVP® XL mid-bore venous closure device and TEG® 6s hemostasis analyzer system's global hemostasis-heparinized neutralization assay cartridge, as well as the acquisition of Advanced Cooling Therapy, Inc. (d/b/a Attune Medical) and other strategic investments to complement our Interventional Technologies portfolio. In Plasma, we continued to advance our market leadership through new technology rollouts across our customer base and market share gains both in the US and internationally, strengthening our foundation during a temporary pullback in collection volumes. In Blood Center, we continued to meet strong demand for our Apheresis products while divesting our Whole Blood product line, helping to better align our resources toward higher margin, higher growth opportunities. In our ongoing efforts to accelerate growth and innovation, we also introduced new Chief Commercial Officer and Chief Operating Officer leadership roles designed to strengthen our strategic execution as we evolve our business. Looking ahead to the final year of our long-range plan in fiscal 2026, we are confident in the foundation we are building to deliver sustained, long-term value to our customers and shareholders.

For further discussion of our fiscal 2025 business highlights and how our fiscal 2025 performance affected our Named Executive Officers' compensation, please see our Compensation Discussion and Analysis beginning on page 22. For additional information on our fiscal 2025 financial results please see our Annual Report on Form 10-K for the fiscal year ended March 29, 2025.

Governance Highlights

The following "Governance Highlights" are for the nine Board members nominated for re-election at our 2025 Annual Meeting of Shareholders, all of whom (with the exception of Christopher A. Simon, our President and Chief Executive Officer) are independent.

BOARD COMPOSITION SNAPSHOT

4 HAEMONETICS CORPORATION | 2025 Proxy Statement

BOARD MEMBERS

Committee Chair

INDEPENDENT DIRECTOR QUALIFICATIONS

As discussed below under “Board Composition and the Director Nomination Process” (beginning on page 9), the Governance and Compliance Committee is responsible for reviewing and assessing the appropriate skills, experience and backgrounds that should be reflected in the composition of the Board. The experience, expertise and diversity represented by the Board as a collective body allow the Board to lead Haemonetics in a manner that serves its shareholders’ interests appropriately. The Governance and Compliance Committee believes that the independent directors on our Board have an effective mix of experience, qualifications, attributes and skills that are important to our business, which include:

CEO or direct profit and

loss accountability

Accountability for medical affairs or

relevant clinical or R&D activities

Responsibility for product development,

innovation and technology

Responsibility or accountability

for enterprise risk management

Other public company

board experience

Responsibility for

operational effectiveness

Experience in financial

compliance and reporting

Responsibility for corporate

strategic planning or major output

Mergers and acquisitions experience

HAEMONETICS CORPORATION | 2025 Proxy Statement 5

BOARD REFRESHMENT

The Board does not endorse arbitrary term limits for director service, nor does it believe in automatic re-nomination until directors reach a mandatory retirement age. The Board and each committee of the Board conduct an annual self-evaluation of their performance, which is an important determinant for Board refreshment. Director feedback solicited from the formal self-evaluation process is discussed during Board and committee meetings and, where appropriate, addressed with management. The Board’s annual self-evaluation process also includes an individual Board member peer review component. The director peer review process was facilitated by our Board Chair in fiscal 2025 with feedback provided to each individual director.

As provided in the Company’s Principles of Corporate Governance, directors generally will not be nominated for re-election at any annual meeting of shareholders following their 75th birthday. To further promote refreshment, and as an alternative to term limits, the Principles of Corporate Governance also provide that the Board will seek to maintain anaverage tenure of ten years or less for its independent Board members as a group (see "Board Composition Snapshot" on page 4 for the current average tenure of our independent Board members). The Board maintains discretion in each case to waive these guidelines for a director if it deems such waiver to be in the best interests of the Company.

How We Think About Board Refreshment

BEST PRACTICES

We are committed to high standards in corporate governance and creating a corporate governance environment that supports the long-term success of our Company. Our governance practices include the following:

6 HAEMONETICS CORPORATION | 2025 Proxy Statement

SHAREHOLDER OUTREACH

The Company is committed to transparent and active engagement with its shareholders. On an ongoing basis, members of senior management meet with shareholders to discuss the Company’s business fundamentals, performance and long-term outlook. Our Board also proactively engages with shareholders on governance and executive compensation matters and other topics of shareholder interest. During the fall and winter of fiscal 2025, our Board Chair (who also Chairs our Governance and Compliance Committee) and our Compensation Committee Chair offered meetings to shareholders that collectively held approximately 53% of our shares outstanding. Together with members of our Legal and Investor Relations teams, these Board members met in the fourth quarter of fiscal 2025 with shareholders representing over 21% of shares outstanding to discuss, among other topics, Haemonetics' corporate strategy and performance, board composition and refreshment, executive compensation, corporate responsibility and other governance matters. Details of shareholder feedback are discussed throughout this Proxy Statement.

For information on how to contact our Board please see "Communications with the Board of Directors" on page 14.

CORPORATE RESPONSIBILITY

At Haemonetics, our corporate responsibility programs and practices inform our corporate strategy and support our Purpose as we strive to drive greater possibilities and meaningfully advance healthcare. How we do this work is equally important.

We are committed to taking the necessary steps across all parts of our business to ensure the long-term health and success of our Company, our colleagues, our customers and our communities. Haemonetics’ corporate responsibility framework augments our corporate strategy by proactively identifying and managing the environmental, social and governance risks and opportunities relevant to our Company and those we serve across four sustainability pillars, as represented in the graphic below:

We target publication of our Corporate Responsibility reports on a biennial basis and currently expect to publish our next Corporate Responsibility report in summer 2025. Our Corp orate Responsibility reports and other information on our website are not incorporated by reference into, and do not form any part of, this Proxy Statement.

HAEMONETICS CORPORATION | 2025 Proxy Statement 7

Performance Highlights

ELEMENTS OF TOTAL COMPENSATION

When setting compensation for our Named Executive Officers, or NEOs, the Compensation Committee focuses on total direct compensation. Total direct compensation includes three major components – base salary, annual short-term incentive compensation and annual long-term incentive compensation – all of which are designed to work together to drive a complementary set of behaviors and outcomes. The following chart illustrates, for fiscal 2025, the target annual compensation mix among the three elements of direct compensation for our Chief Executive Officer and, on average, for our other NEOs. For more information, see "Target Annual Compensation Mix" on page 29.

(1)Long-term incentive compensation reflects grant value of fiscal 2025 annual long-term incentive awards granted to our Named Executive Officers. For more information, see "Individual Fiscal 2025 Long-Term Incentive Awards" beginning on page 34.

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this Proxy Statement that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this Proxy Statement may include, without limitation, statements regarding (i) plans and objectives of management for operations of the Company, including plans or objectives related to the Company’s strategy for growth; product development, commercialization and anticipated benefits; regulatory approvals; the impact of acquisitions and divestitures; market position and expenditures; and the Company’s market and regional alignment and portfolio rationalization initiatives; (ii) estimates or projections of future financial results, financial condition, capital expenditures, capital structure or other financial items, including with respect to the share repurchase program; and (iii) the assumptions underlying or relating to any statement described in points (i) and (ii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Factors that may cause actual results to differ materially from those contemplated by the statements in this Proxy Statement can be found in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended March 29, 2025 under the headings "Cautionary Statement Regarding Forward-Looking Information" and "Risk Factors" and in our other filings with the Securities and Exchange Commission ("SEC"). The Company does not undertake to update these forward-looking statements.

This Proxy Statement contains statements regarding individual and Company performance objectives and targets. These objectives and targets are disclosed in the limited context of our compensation plans and programs and should not be understood to be statements of management’s future expectations or estimates of future results or other guidance. We specifically caution investors not to apply these statements to other contexts.

8 HAEMONETICS CORPORATION | 2025 Proxy Statement